Compare PMN & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMN | ALUR |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5M | 18.9M |
| IPO Year | N/A | N/A |
| Metric | PMN | ALUR |
|---|---|---|
| Price | $7.23 | $1.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $72.67 | $9.25 |
| AVG Volume (30 Days) | 31.5K | ★ 58.2K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.27 | $1.02 |
| 52 Week High | $39.75 | $16.81 |
| Indicator | PMN | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 35.76 |
| Support Level | $8.00 | $1.29 |
| Resistance Level | $8.73 | $1.48 |
| Average True Range (ATR) | 0.56 | 0.11 |
| MACD | -0.39 | -0.02 |
| Stochastic Oscillator | 9.86 | 9.18 |
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.